Clinical trial · Interventional
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
Eastern Hepatobilliary Surgical Hospital
NCT00820053CI-TRIAL-00021600completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group. The time to recurrence ,the overall survival as well as the incidence of complications after therapy was observed to confirm the role of adjuvant TACE.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epirubicin and lipiodol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- no adjuvant TACE
- description
- controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
- type
- EXPERIMENTAL
- label
- adjuvant TACE
- description
- patients who adjuvant TACE after liver resection
- interventionNames
- Drug: epirubicin and lipiodol
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2010
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients \> 18 years and \<=70 years of age. 2. Patients with HCC who received curative liver resection (R0). 3. Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. 4. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hb ≥90g/L,WBC ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³ . 5. Karnofsky Performance Score performance over 60 . 6. Patients who can understand this trial and have signed information consent Exclusion Criteria: 1. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction,which may affect the treatment of liver cancer. 2. Patients with other diseases which may affect the treatment mentioned here. 3. Patients with medical history of other malignant tumors. 4. Subjects participating in other clinical trials. 5. Extrahepatic metastasis, portal vein or other major vascular involvement. liver function:Child C. 6. Patients would not sign the consent to the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.